A multisectoral coalition dedicated to reducing cardiovascular disease in the Asia-Pacific region through collaborative efforts and innovative strategies.
-Angsana Health
-Asia Pacific Federation for Clinical Biochemistry and Laboratory Medicine
-College of Community Pharmacy Thailand
-Community Pharmacy Association Thailand
-Global Alliance for Patient Access
-Global Heart Hub
-Heart Support Australia
-Korea Biomedical Review
-Maaedicare Charitable Foundation
-Universiti Teknologi Mara
-Volunteering Heart Foundation
-Amgen
-Novartis
-Roche
Cardiovascular disease (CVD) is the leading cause of death in the Asia-Pacific, with over 10 million dying in 2019 alone and incurring an estimated US$177 billion in direct costs. CVD is especially lethal because it can go undetected until someone experiences a heart attack, stroke, cardiac arrest, or heart failure (which has a worse 5-year prognosis than some cancers). These create health, social, and economic costs for patients, caregivers, and health systems.
There is a need for concerted action to address specific gaps in CVD prevention and control in the Asia-Pacific. Public and policy awareness of the burden of CVD on health systems is also low—the APAC CVD Alliance in June 2023 to address this gap.
The APAC CVD Alliance is a multisectoral coalition comprising patient organizations, academia, implementation partners, global health foundations, policymakers, and corporate partners. The Alliance intends to inspire policy change by elevating public and policy awareness of the urgent need to tackle CVD across prevention, early detection, treatment, and rehabilitation.
The Mission of the CVD Alliance is to improve heart health and reduce the CVD burden for patients, societies, and economies in the Asia-Pacific. Its objectives include:
Partnering patients and health systems across the care continuum of prevention, early detection, treatment, and rehabilitation
Break down silos between patients, policymakers, and professionals
Share the latest research and insights on policy gaps in CVD in the Asia Pacific
Support policy change and the implementation of sustainable, scalable CVD innovations
Advocate for investment in productive and healthy generations to reduce death and disability across all ages
Strategic Partners
Advisors
Asia Pacific Countries
A white paper titled “Call for Cohesive Action: Redefining Cardiovascular Care in the Asia-Pacific””
This flagship Alliance report suggests that a cohesive strategy is needed to tackle CVD effectively. It challenges the myth that CVD only affects those in old age, urban, or rich populations. A cohesive strategy must be patient-centered across prevention, early detection, treatment, and rehabilitation - ultimately to achieve three outcomes: reduce premature deaths; reduce hospitalizations and re-hospitalizations, and slow growth of new CVD patients.
Policy advocacy to governments, payers, and global health institutions - organizing country dialogues in Thailand, India, Malaysia, and Korea (2024), and outreach to regional forums focused on health including APEC and ASEAN.
People-centered activities - patients' voice in the center with the APAC CVD Patients' Roundtable (Oct 2024).
Launch of a regional report titled A Call for Cohesive Action: Redefining Cardiovascular Care in the Asia-Pacific (2023).
Launch of the inaugural Asia-Pacific Heart Summit (Oct 2024) to unite all workstreams together.
Since last year, we have been offering the Aireen device in our Health+ diabetes surgery. We talked to Barbara Jónová, MD, about what Aireen is and what it can do.
Since last year, we have been offering the Aireen device in our Health+ diabetes surgery. We talked to Barbara Jónová, MD, about what Aireen is and what it can do.
Since last year, we have been offering the Aireen device in our Health+ diabetes surgery. We talked to Barbara Jónová, MD, about what Aireen is and what it can do.
Since last year, we have been offering the Aireen device in our Health+ diabetes surgery. We talked to Barbara Jónová, MD, about what Aireen is and what it can do.
Since last year, we have been offering the Aireen device in our Health+ diabetes surgery. We talked to Barbara Jónová, MD, about what Aireen is and what it can do.
Since last year, we have been offering the Aireen device in our Health+ diabetes surgery. We talked to Barbara Jónová, MD, about what Aireen is and what it can do.
